Join Our Triple O Newsletter List And Stay Informed.

Do you or someone you know have any of the following conditions?

HIV?
Hepatitis C?
Hepatitis B?
Lipodystrophy?
C. Diff Colitis?
Pneumonia?
Skin Infections such as abscesses or cellulitis?

If you answered YES, please speak to one of research team members to learn more about a clinical trial you may qualify for.
Treatment and office visits are free, if […]

Fri, Nov 21, 2014
Source: Triple O Research Newsletter

Unger, N., Osiyemi, O., Richardson, R., & Menajovsky, J., Ceftaroline and gentamicin for the treatment of daptomycin-non-susceptible meticillin-resistant Staphylococcus aureus bacteraemia and endocarditis in a pregnant patient. JMM Case Reports, 2014, 1-3. […]

Fri, Nov 21, 2014
Source: Triple O Research Newsletter

Did you know at the end of 2009, it was estimated 1.1 million people, aged 13 and older, were living with HIV in the
United States. Approximately 207,600 (18.1%) have not yet been diagnosed.
Please help us reduce this disparity!
Effective September 1, 2013, Triple O Research Institute, in collaboration with Triple O […]

Fri, Nov 21, 2014
Source: Triple O Research Newsletter

Triumeq is now FDA approved!
In the past month, The Food and Drug Administration of the United States approved Triumeq (dolutegravir/abacavir/lamivudine).
Triumeq is GlaxoSmithKline’s first single tablet regimen (STR) for the treatment of HIV.
Triumeq is the fourth single tablet regimen currently on the market. Certain patients with a history of HIV have […]

Fri, Nov 21, 2014
Source: Triple O Research Newsletter